Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive Anakinra for Severe CRS Prevention in CAR T-Cell Therapy for B-ALL
NCT06703216Phase 2Withdrawn
- Start
- Oct 2026
- Primary completion
- Aug 2029
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of anakinra in cytokine release syndrome (CRS). Planned start Oct 2026; status: withdrawn.
02
Drugs
anakinra
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT06703216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703216.